EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

INVEX Therapeutics Ltd (IXC) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of INVEX Therapeutics Ltd A$0.07, price A$0.11, upside -33.3%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · AU · ISIN AU0000048621

IT Thin data Sep 23, 2026

INVEX Therapeutics Ltd

IXC · AU

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value A$0.0700 · Overvalued (−33%)
!Quality 57/100
!Expensive Growth (revenue 5y +6.7 %/yr)
!negative free cash flow
!Mixed vs. peers (4/7)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch INVEX Therapeutics Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.7500 A$0.0600 Fair Value A$0.0700 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range A$0.0600 – A$0.7500 · fair‑value band A$0.0500 – A$0.0900 · the A$0.1050 price screens above the A$0.0700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow INVEX Therapeutics in your weekly email

Every Wednesday you see whether INVEX Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

Show more

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.

Stock analysis

INVEX Therapeutics Ltd (IXC) currently trades at A$0.1050, while our model-based Fair Value estimate is A$0.0700, implying the stock looks roughly 50.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: A$0.0500 (bear) to A$0.0900 (bull), the price of A$0.1050 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

INVEX Therapeutics Ltd reported revenue of A$229K in FY2025 versus A$159K in FY2021, a compound +9.6%/yr. Reported net income was −A$477K in FY2025.

Key figures

Market cap A$7.9M (≈ $5.6M) · P/S ratio 34.4 · EPS (TTM) A$−0.0100 · Return on equity −16.8% · Return on assets (EBIT) −21.3% · Operating margin −96,227% · Revenue (TTM) A$229K · Revenue growth (YoY) −44.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −33%, IXC screens richer than that median.

Fair Value models

Bear A$0.0500 Fair Value A$0.0700 Bull A$0.0900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) A$0.0300 A$0.0500 A$0.0700 51
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0300 A$0.0500 A$0.0700 51

Open the full fair value analysis →

Notify me when IXC reaches fair value

Put IXC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 57/100

Of which business quality 57 · Market factors (momentum, volatility) 33

Profitability 2
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 40
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 78
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−81.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+247.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,985.6% (2020) → −309.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IXC screens 50% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare INVEX Therapeutics Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Top 25%
Fair Value upside −33% · Above median
Profitability
Return on assets −13% · Below median
Growth and dividend
Revenue growth −45% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.06× · Cheaper than median
P/S (TTM) 24.34× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

INVEX Therapeutics Ltd · Fair Value
A$0.0700 −50%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "INVEX Therapeutics Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IXC

Frequently asked questions

Is INVEX Therapeutics Ltd (IXC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.0700 versus a price of A$0.1050, about −33% upside (overvalued).
What is the fair value of IXC?
Our model-based fair value for INVEX Therapeutics Ltd is A$0.0700 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.1050.
What is the quality score of IXC?
INVEX Therapeutics Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for INVEX Therapeutics Ltd (IXC)?
Our model-based price target is the fair value of A$0.0700 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario A$0.0500, optimistic scenario A$0.0900. It is a calculation from audited fundamentals, not an analyst target.
What is the INVEX Therapeutics Ltd stock forecast for 2026?
Our models put fair value at A$0.0700, about −33% upside versus a price of A$0.1050 (overvalued). Cautious scenario A$0.0500, optimistic scenario A$0.0900. The calculation is refreshed regularly with new filings.
What is the revenue of INVEX Therapeutics Ltd (IXC)?
INVEX Therapeutics Ltd reported trailing-twelve-month revenue of about A$229K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of INVEX Therapeutics Ltd (IXC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For INVEX Therapeutics Ltd it is A$0.0700 per share (as of Sep 23, 2026), against a price of A$0.1050. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is INVEX Therapeutics Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IXC trades above its calculated fair value: price A$0.1050, fair value A$0.0700, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IXC?
No. The price is what the market pays today (A$0.1050); the fair value is what the company's own numbers justify (A$0.0700). For INVEX Therapeutics Ltd the two are A$0.0350 per share apart. That gap is exactly why we show both numbers side by side.
How much is INVEX Therapeutics Ltd worth?
The market values INVEX Therapeutics Ltd at about A$7.9M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.1050; our models calculate a fair value of A$0.0700 per share.
What do the bullish and bearish scenarios say about IXC?
Our models span a range for INVEX Therapeutics Ltd: cautious scenario A$0.0500, base A$0.0700, optimistic A$0.0900 per share (as of Sep 23, 2026, price A$0.1050). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of INVEX Therapeutics Ltd (IXC)?
Balance-sheet figures for INVEX Therapeutics Ltd (as of Sep 23, 2026): return on equity −16.8%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is IXC from its 52-week high?
INVEX Therapeutics Ltd trades at A$0.1050, about 34% below its 52-week high of A$0.1600 and 17% above the low of A$0.0900 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0700 is for.
Which stocks are comparable to INVEX Therapeutics Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is INVEX Therapeutics Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.1050, calculated fair value A$0.0700 (−33%), Quality Score 57/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IXC calculated?
We run INVEX Therapeutics Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. INVEX Therapeutics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of INVEX Therapeutics Ltd (IXC)?
The closing price on Sep 24, 2026 was A$0.1050. Our model-based fair value is A$0.0700, about −33% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with INVEX Therapeutics Ltd right now?
The price sits above even our optimistic bull case (A$0.0900). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of INVEX Therapeutics Ltd

How large is the market capitalisation of INVEX Therapeutics Ltd (IXC)?
The market capitalisation of INVEX Therapeutics Ltd is A$7.9M (≈ $5.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of INVEX Therapeutics Ltd (IXC)?
The price-to-sales ratio of INVEX Therapeutics Ltd is 34.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of INVEX Therapeutics Ltd (IXC)?
Earnings per share at INVEX Therapeutics Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of INVEX Therapeutics Ltd (IXC)?
The return on equity (ROE) of INVEX Therapeutics Ltd is −16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of INVEX Therapeutics Ltd (IXC)?
On an EBIT basis the return on assets of INVEX Therapeutics Ltd is −21.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of INVEX Therapeutics Ltd (IXC)?
The operating margin of INVEX Therapeutics Ltd is −96,227% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at INVEX Therapeutics Ltd (IXC)?
Revenue at INVEX Therapeutics Ltd is growing −44.9% versus a year earlier (3y avg +7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does INVEX Therapeutics Ltd (IXC) generate?
The free cash flow of INVEX Therapeutics Ltd is −A$653K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does INVEX Therapeutics Ltd (IXC) hold?
INVEX Therapeutics Ltd holds more cash than debt, A$5.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch INVEX Therapeutics Ltd in the live analysis

One click puts INVEX Therapeutics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.